Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555906 · ClinicalTrials.gov registry record · Phase 2
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
A Phase 2 study of Multiple Myeloma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 19
- Study locations
NCT00555906: Completed Phase 2 study of Multiple Myeloma, sponsored by Pfizer.
NCT00555906 is a Phase 2 study of Multiple Myeloma that has completed, run by Pfizer. The registered enrollment target is 53 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 19 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00555906, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® \[bortezomib\] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
Primary Outcome
MTD=highest dose level for which no more than 1 out of 6 participants experienced dose-limiting toxicity (DLT). DLT=any of the following treatment-related events: Absolute neutrophil count (ANC) less than (\<)1000/microliter (mcL) (Grade 3 neutropenia) associated with documented infection/fever \>=38.5degrees Celsius (C); Grade \>=3 nonhematologic treatment-related toxicity, except those that were not maximally treated or considered tolerable, Grade 3 corrected QT interval (QTc) prolongation (QT
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG PD 0332991
Study Locations (19)
Missouri
- Washington University School of Medicine - St Louis
- Barnes-Jewish Hospital - St Louis
- Washington University School of Medicine - St Louis
Other
- Vseobecna fakultni nemocnice v Praze - Prague
- Universitaetsklinikum Heidelberg - Heidelberg
- Klinikum Johannes-Gutenberg -Universitaet, III. Medizinische Klinik und Poliklinik - Mainz
Illinois
- Northwestern Medical Faculty Foundation - Chicago
- Northwestern Memorial Hospital/Main Labs - Chicago
Kansas
- University of Kansas Medical Center - Kansas City
- University of Kansas Cancer Center and Medical Pavilion - Westwood
New York
- Roswell Park Cancer Institute - Buffalo
- New York Presbyterian, Weill Cornell Medical College - New York
Pennsylvania
- University of Pennsylvania Abramson Cancer Center - Philadelphia
- University of Pittsburgh Cancer Institute - Pittsburgh
South Carolina
- Hollings Cancer Center - Charleston
- Medical University of South Carolina - Charleston
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT00555906 record still lists
NCT00555906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00555906 lists 19 locations in 10 states (Missouri, Other, Illinois).
Frequently Asked Questions
What is clinical trial NCT00555906 about?
NCT00555906 is a clinical study titled "An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.". This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® \[bortezomib\] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
What is the current status of trial NCT00555906?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2008-01. Estimated completion is 2013-03.
What conditions does trial NCT00555906 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00555906?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), PD 0332991 (DRUG).
Who is sponsoring clinical trial NCT00555906?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00555906 being conducted?
This trial has 19 study locations across Illinois, Kansas, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00555906's enrollment target sits among peer trials
53 243rd of 438 higher than 195 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
- NCT05045950 · 53 participants · Phase 2
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia